China's Hansoh signs up to $1.45 billion deal for colorectal cancer drug with Roche

Reuters

10/17

UPDATE 1-China's Hansoh signs up to $1.45 billion deal for colorectal cancer drug with Roche

Adds further details from paragraph 2 onwards

Oct 17 (Reuters) - Chinese biotech Hansoh Pharma 3692.HK said on Friday it had signed a licence agreement worth up to $1.45 billion with Roche ROG.S for an investigational treatment of colorectal cancer and other solid tumours.

Hansoh Pharma units Shanghai Hansoh Biomedical and Changzhou Hansoh Pharmaceutical will grant Roche subsidiary F. Hoffmann-La Roche an exclusive worldwide licence to develop, manufacture and commercialise the product.

The licence excludes rights in the Chinese Mainland, Hong Kong, Macau and Taiwan.

The licensors will receive an upfront payment of $80 million and be eligible to receive up to $1.45 billion in milestone payments associated with the development, regulatory approval and commercialisation of the product, among others.

(Reporting by Sneha Kumar in Bengaluru; Editing by Shailesh Kuber and Subhranshu Sahu)

((Sneha.Kumar@thomsonreuters.com))

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2576772937"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2576772937\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2576772937?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-17 07:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2576772937","market":"us","top_or_hot":-1,"title":"China's Hansoh signs up to $1.45 billion deal for colorectal cancer drug with Roche","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>UPDATE 1-China's Hansoh signs up to $1.45 billion deal for colorectal cancer drug with Roche</title></head><body><p>Adds further details from paragraph 2 onwards</p><p><span>Oct 17 (Reuters)</span><span> - </span>Chinese biotech Hansoh Pharma <span>3692.HK</span> said on Friday it had signed a licence agreement worth up to $1.45 billion with Roche <span>ROG.S</span> for an investigational treatment of colorectal cancer and other solid tumours.</p><p>Hansoh Pharma units Shanghai Hansoh Biomedical and Changzhou Hansoh Pharmaceutical will grant Roche subsidiary F. Hoffmann-La Roche an exclusive worldwide licence to develop, manufacture and commercialise the product.</p><p>The licence excludes rights in the Chinese Mainland, Hong Kong, Macau and Taiwan.</p><p>The licensors will receive an upfront payment of $80 million and be eligible to receive up to $1.45 billion in milestone payments associated with the development, regulatory approval and commercialisation of the product, among others. </p><p> (Reporting by Sneha Kumar in Bengaluru; Editing by Shailesh Kuber and Subhranshu Sahu)</p><p> ((Sneha.Kumar@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>China's Hansoh signs up to $1.45 billion deal for colorectal cancer drug with Roche</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChina's Hansoh signs up to $1.45 billion deal for colorectal cancer drug with Roche\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-17 07:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>UPDATE 1-China's Hansoh signs up to $1.45 billion deal for colorectal cancer drug with Roche</title></head><body><p>Adds further details from paragraph 2 onwards</p><p><span>Oct 17 (Reuters)</span><span> - </span>Chinese biotech Hansoh Pharma <span>3692.HK</span> said on Friday it had signed a licence agreement worth up to $1.45 billion with Roche <span>ROG.S</span> for an investigational treatment of colorectal cancer and other solid tumours.</p><p>Hansoh Pharma units Shanghai Hansoh Biomedical and Changzhou Hansoh Pharmaceutical will grant Roche subsidiary F. Hoffmann-La Roche an exclusive worldwide licence to develop, manufacture and commercialise the product.</p><p>The licence excludes rights in the Chinese Mainland, Hong Kong, Macau and Taiwan.</p><p>The licensors will receive an upfront payment of $80 million and be eligible to receive up to $1.45 billion in milestone payments associated with the development, regulatory approval and commercialisation of the product, among others. </p><p> (Reporting by Sneha Kumar in Bengaluru; Editing by Shailesh Kuber and Subhranshu Sahu)</p><p> ((Sneha.Kumar@thomsonreuters.com))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1191","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251016:nL6N3VX19N:1","article_id":"2576772937","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2576772937","pubTimestamp":1760658183,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"UPDATE 1-China's Hansoh signs up to $1.45 billion deal for colorectal cancer drug with RocheAdds further details from paragraph 2 onwardsOct 17  - Chinese biotech Hansoh Pharma 3692.HK said on Friday it had signed a licence agreement worth up to $1.45 billion with Roche ROG.S for an investigational treatment of colorectal cancer and other solid tumours.Hansoh Pharma units Shanghai Hansoh Biomedical and Changzhou Hansoh Pharmaceutical will grant Roche subsidiary F. Hoffmann-La Roche an exclusive worldwide licence to develop, manufacture and commercialise the product.The licence excludes rights in the Chinese Mainland, Hong Kong, Macau and Taiwan.The licensors will receive an upfront payment of $80 million and be eligible to receive up to $1.45 billion in milestone payments associated with the development, regulatory approval and commercialisation of the product, among others.   ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1191":"制药","BK1583":"高瓴概念","BK1589":"北水核心资产","03692":"翰森制药"},"translate_title":"中国豪森与罗氏签署价值14.5亿美元的结直肠癌药物协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03692":0.9},"content_text":"UPDATE 1-China's Hansoh signs up to $1.45 billion deal for colorectal cancer drug with RocheAdds further details from paragraph 2 onwardsOct 17 (Reuters) - Chinese biotech Hansoh Pharma 3692.HK said on Friday it had signed a licence agreement worth up to $1.45 billion with Roche ROG.S for an investigational treatment of colorectal cancer and other solid tumours.Hansoh Pharma units Shanghai Hansoh Biomedical and Changzhou Hansoh Pharmaceutical will grant Roche subsidiary F. Hoffmann-La Roche an exclusive worldwide licence to develop, manufacture and commercialise the product.The licence excludes rights in the Chinese Mainland, Hong Kong, Macau and Taiwan.The licensors will receive an upfront payment of $80 million and be eligible to receive up to $1.45 billion in milestone payments associated with the development, regulatory approval and commercialisation of the product, among others.  (Reporting by Sneha Kumar in Bengaluru; Editing by Shailesh Kuber and Subhranshu Sahu) ((Sneha.Kumar@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}